Copyright HEMO SAPIENS^®

HEMO SAPIENS INC. (HSI) - a California Corporation - is a high-tech medical company, which has developed Thoracic Electrical Bioimpedance (TEB)-based TEBCO^® OEM Module for continuous, noninvasive measurement of stroke index, cardiac index, and other cardiodynamic, hemodynamic and respiratory parameters, and an array of PC-based HOTMAN^® Systems with three different softwares for assessment, monitoring and management of complete hemodynamics and oxygen transport dynamics of the entire human population: (a) neonates & pediatrics (HOTMAN^®-N/P), (b) adult men & postmenopausal women (HOTMAN^®-BAS), and (c) gravidas & nongravidas (HOTMAN^®-PRG). The Company's HOTMAN^® Systems implement a proprietary hemodynamic assessment, monitoring and management method, and means for real-time hemodynamic and oxygen transport data communication between patients and health care providers. HOTMAN^® System is technologically, hemodynamically, economically and clinically more advanced than its alternatives: CardioDynamics' BioZ, Philips ICG Monitor and Analogic's LifeGard. Afterall, these products are just ICG monitors and offer no hemodynamic management capability.

Dr. B. Bo Sramek, the founder of HSI, is a renowned authority on Thoracic Electrical Bioimpedance (TEB) technology and hemodynamic management. Dr. Sramek has a long history of advancing TEB/ICG (Thoracic Electrical Bioimpedance/Impedance Cardiography) technology to its current state-of-the-art: He founded BoMed in 1980. After BoMed became CardioDynamics in 1993, he left that company in 1994 to start HSI. His novel theory of beat-hemodynamics and hemodynamic management is a harbinger of profound changes in cardiovascular medicine and health care, transforming it from a reactive care to a proactive care:

• An underlying feature of the reactive care is its focus on hemodynamic monitoring, i.e., obtaining an early warning of an impending cardiovascular disaster and only then responding/reacting to it. The hemodynamic management methodology under reactive care is trial-and-error.
• In contrast, the underlying philosophy of proactive care is the hemodynamic management, i.e., obtaining a continuous and real-time information what cardioactive and vasoactive therapy, and in what titration, to administer to a patient as to maintain his hemodynamics and perfusion dynamics in normohemodynamic and normoperfusion states = the therapeutic goal.

HSI proprietary TEB is implemented in the TEBCO^® OEM Module for continuous noninvasive measurement of stroke index, cardiac index and other cardiodynamic, hemodynamic and respiratory parameters. TEBCO^® OEM Module can be incorporated into any existing patient monitoring system or integrated into a personal computer to create a stand-alone cardiac output monitor. The Company's Product Development Department will re-design the TEBCO^® OEM Module to match specific customer's system hardware and software requirements.

EXT-TEBCO^® contains the TEBCO^® OEM Module in a small, external enclosure for cardiac output, cardiodynamic and hemodynamic monitoring with notebooks and nondedicated PCs.

HSI proprietary hemodynamic monitoring and management method is implemented in an array of HOTMAN^® Systems, designed for noninvasive assessment, monitoring and management of complete hemodynamics and oxygen transport dynamics across the entire patient population, ranging from neonates through adults, and including women during pregnancy. An additional capability of all HOTMAN^® softwares is to model hemodynamic effects of any cardio- and vasoactive drug without exposing patients to potentially dangerous side effects of incorrectly prescribed pharmaceuticals. Its built-in telemedicine features communicate patient data via Internet or Intranet and the software can be directly implemented into network servers. This real-time data collection of patients' hemodynamics and their hemodynamic vectorial responses to drug therapy is invaluable to insurance companies in establishing guidelines for drug prescriptions.

The Company has the ISO 13485:2003 Certification.
Both TEBCO^® and HOTMAN^® System have the FDA 510(k) marketing approval. In addition, the HOTMAN^® System has the CE-Certificate.

The Slide Rule for Hemodynamic Management of Adults enables utilization of modern hemodynamic management method even in patients in whom the hemodynamic parameters are measured invasively or who are monitored by ICG/TEB Monitors, that do not provide the hemodynamic management information.
.

The all-noninvasive and neoteric features of Company's products may help to eliminate infections, risks, morbidities and mortalities associated with use of invasive procedures (catheters).

Current patient monitors and noninvasive cardiac output monitors of other TEB/ICG (ICG = Impedance Cardiography) companies provide only a partial, fragmented and, possibly, even an incorrect information about a patient's hemodynamics. In addition, these devices provide no information about oxygen transport dynamics - the highest hierarchy information about the functionality of cardiovascular system.

In contrast, the Company's HOTMAN^® Systems display continuously an easily interpretable and complete information about hemodynamics and oxygen transport dynamics within one monitoring screen. The data acquisition is automatic, hands-free and operator-independent.

Current patient monitors do not provide the attending clinician with the hemodynamic management information, i.e., what kind of therapy and at what titration to administer to a patient (i.e, a choice of a combination of volume expansion/diuresis, positive/negative inotropic therapy, vasoconstriction/vasodilation, positive/negative chronotropic therapy) to correct an observed abnormal hemodynamic state. In absence of this hemodynamic management information, the clinician has to rely on his knowledge and past experience to manage a patient. Due to incomplete information available to him from current monitors, he has to use a trial-and-error management methodology for selection of optimal therapy. However, trial-and-error takes time... In many cases, the optimal therapy is never found this way. Trial-and-error also results in waste of expensive cardio- and vasoactive drugs.

In contrast to this slow and cumbersome process described above, the Company's HOTMAN^® Systems provide complete hemodynamic management information by identifying in real-time the causes of observed abnormal hemodynamic and perfusion states and their percentage deviations. Their hemodynamic management screen identifies the percentage deviations in three hemodynamic modulators (volemia, inotropy and vasoactivity) and in the perfusion flow modulator (chronotropy). Therapeutic correction of these deviations then results not only in normovolemia, normoinotropy, normovasoactivity and normochronotropy, but in a normohemodynamic and normperfusion state as well.

Most of oral cardioactive and vasoactive drugs used to manage cardiovascular disorders have extended pharmacological effects, spanning from hours to days. Their incorrect selection and administration, which is a natural result of current trial-and-error management methodology, therefore, may expose the patient to a prolonged undesirable side effects or compromised hemodynamic state. The proprietary modeling of hemodynamic effects of cardio- and vasoactive drugs, available with all HOTMAN^® Systems, enables the clinician to visualize hemodynamic effects of any planned drug on the System's hemodynamic modeling screen, thus preventing an undesirable exposure to incorrectly selected drug(s). This feature also is an important educational tool in medical and nursing schools.

With any HOTMAN^® System, the clinician can select up to six parameters from any of the monitored parameters and study their trends in time. This feature provides for a more intricate understanding of a patient's cardiovascular system, the inter-relationships between cardiovascular parameters and their variation as a function of time, and enables the clinician to reach a more precise diagnosis.

The telemedicine features of the Company's HOTMAN^® Systems provide direct interface with Internet/Intranet and other computer and medical networks and help the clinicians to assess, monitor, diagnose and consult a patient in a matter of minutes and manage him into an optimal hemodynamic state (therapeutic goal), independent of the momentary locations of the clinician, consultant and patient.

The TEB measurement current of the Company's TEBCO^® and HOTMAN^® Systems is several hundred times lower than the measurement current utilized by products of other TEB/ICG companies, making it that many times safer.

Complete hemodynamic database, collected by HOTMAN^® Systems, can be used for setting new standards for cardiovascular assessment and risk management, leading into a higher awareness, economically managed cardiovascular care and improved outcomes.